TECHNOLOGY
A new era of AI-based vaccine platforms
VitraBio, through AI-VLP technology
Provides more precise and safe immune solutions
The standard for next-generation vaccines begins here and now
Next-Generation AI-Powered VLP Platform
Next-generation AI-based VLP vaccine platform
VitraBio combines AI technology with virus-like particles (VLPs)
To develop a safer and more efficient next-generation vaccine platform
Going beyond the limitations of traditional vaccine technologies
With non-infectious particle-based precision immune response induction technology
We proactively respond to future pandemics and emerging diseases
AI-VLP Platform
As a flexible system capable of customized antigen design
It can be expanded from pandemic response to personalized treatment
Induction of strong immune response
It effectively stimulates the body's immune system with a structure similar to real viruses
High safety
There is no risk of infection as non-infectious particles without genetic material are used
Customizable design available
Antigen design tailored to specific diseases enables the development of a diverse vaccine lineup
Strengths of the AI-VLP Platform
AI-based design optimization
Through precise VLP structure design using artificial intelligence
Rapidly derives vaccine candidates and targets various pathogens
Enables the rapid production of customized protein antigens
Broad applicability
The AI-VLP platform can be applied to a wide range of diseases including infectious diseases, cancer, and allergies, as well as the development of human and animal vaccines, flexibly supporting disease-specific immune design.
Efficient production system
Smartly designed VLPs are produced with high efficiency and demonstrate superior performance in safety, scalability, and cost-effectiveness compared to conventional vaccines